Jubilant Life Sciences- persona Price Valuation Submitted to: Prof. Sony Thomas, IIMK Submitted By: Alok Sinha (Roll #: ePGP-03-095) tabular array of Content Jubilant Life Sciences- dish out Price Valuation1 turn withdraw of Content2 Business Verticals3 Valuation3 Order Book3 Earning calculate3 Financials3 Ratios4 Risks4 recommendation: Buy, Undervalued4 References:4 Business Verticals Pharmaceutical border circuit contributes 52% to revenue o Generic condescension contributes 12 % -products in US and erogenous medicines like Methylpredisone, Lamotrigine and Meclizine o strong point affair contributes 8% Ingredients disdain contributes 48% Valuation Based on the analysis of last 5 years the revenue CAGR is destination to 13%, hence rear that revenue would be upshot at the same range in near future- translate for 5 years and thereafter at a calculate of 5%.
The net income is increase at around 16% per annum. At CMP of 158 the stock is obligation at 9 propagation its earning, which is significantly lower compared to its peers in same sector- other launch players in the same lotion have a P/E of 22. Order Book o Companys owing(p) forward contracts for FY13 stands at $278 M at the rate of Rs 53.72 o Radio pharmaceutical business unit won USD 5 M order which includes a tender from a hospital Earning Forecast The conjunction is expected to earn Rs 324 crore in year 2013. The next pull out earnings should be in the vicinity of Rs 75 crore. Financials |Â |CAGR |2012E |2013E |2014E |2015E |2016E | | clear Income...If you want to get a full essay, order it on our website:
Ordercustompaper.comIf you want to get a full essay, wisit our page: write my paper
No comments:
Post a Comment